Patents by Inventor Annie Yang Weaver

Annie Yang Weaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETICALLY ENGINEERED ANTI-CD19 CAR-T CELLS FOR USE IN TREATING B-CELL MALIGNANCIES
    Publication number: 20240115703
    Abstract: Methods for treating B-cell malignancies such as relapsed and/or refractory B-cell malignancies with a population of genetically engineered T cells expressing a chimeric antigen receptor (CAR) targeting CD19 and having multiple genetic edits, including a disrupted TRAC gene, a disrupted ?2M gene, a disrupted Regnase 1 gene, and/or a disrupted TGFBRII gene.
    Type: Application
    Filed: October 6, 2023
    Publication date: April 11, 2024
    Inventors: Ziliang LI, Annie Yang WEAVER, Sarah COHEN, Ewelina MORAWA
  • ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20240076374
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 18, 2023
    Publication date: March 7, 2024
    Inventors: James William WEST, Jason Gary SAGERT, Jonathan Alexander TERRETT, Annie Yang WEAVER, Luc Roland DESNOYERS, Shweta SINGH
  • Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
    Patent number: 11753466
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 12, 2023
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • GENETICALLY ENGINEERED T CELLS EXPRESSING BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN CANCER THERAPY
    Publication number: 20230220059
    Abstract: Genetically engineered T cells expressing a chimeric antigen receptor (CAR) that binds B-cell maturation antigen (BCMA) and uses thereof for treating multiple myeloma, for example, refractory and/or relapsed multiple myeloma. The genetically engineered T cells may comprise a disrupted endogenous TRAC gene and/or a disrupted endogenous ?2M gene.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 13, 2023
    Inventors: Jonathan Alexander TERRETT, Ewelina MORAWA, Jason SAGERT, Annie Yang WEAVER
  • ANTI-CD71 ANTIBODIES, ACTIVATABLE ANTI-CD71 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20220306759
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: February 8, 2022
    Publication date: September 29, 2022
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • CANCER TREATMENT USING CD38 INHIBITOR AND/OR LENALIDOMIDE AND T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20220202859
    Abstract: Combined therapy for treating multiple myeloma (MM), comprising (a) a population of genetically engineered T cells, which may express a chimeric antigen receptor (CAR) that binds B-cell maturation antigen (BCMA), and (b) an anti-CD38 antibody such as daratumumab or lenalidomide or a derivative thereof.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 30, 2022
    Inventors: Jonathan Alexander TERRETT, Ewelina MORAWA, Jason SAGERT, Annie Yang WEAVER
  • Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
    Patent number: 11267896
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: March 8, 2022
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220023439
    Abstract: Provided herein are activatable antibodies that when activated specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 1, 2019
    Publication date: January 27, 2022
    Inventors: Lori CARMAN, Rachel HUMPHREY, W. Michael KAVANAUGH, Jonathan A. TERRETT, Annie Yang WEAVER, Matthias WILL
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210100913
    Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 21, 2020
    Publication date: April 8, 2021
    Inventors: Lori CARMAN, Rachel HUMPHREY, W. Michael KAVANAUGH, Jonathan TERRETT, Annie Yang WEAVER, Matthias WILL
  • ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20200291113
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 20, 2019
    Publication date: September 17, 2020
    Inventors: James William WEST, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
    Patent number: 10745481
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: August 18, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
    Patent number: 10577420
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 3, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Antibodies that bind activatable antibodies and methods of use thereof
    Patent number: 10568977
    Abstract: The invention relates generally to antibodies and antigen-binding fragments thereof that bind activatable antibodies and/or conjugated activatable antibodies and methods of making and using these antibodies that bind activatable antibodies and/or conjugated activatable antibodies.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: February 25, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Luc Roland Desnoyers, Tony W. Liang, Annie Yang Weaver
  • ANTI-ITGA3 ANTIBODIES, ACTIVATABLE ANTI-ITGA3 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190309072
    Abstract: The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: January 18, 2019
    Publication date: October 10, 2019
    Inventors: Jason Gary SAGERT, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
  • ANTI-CD71 ANTIBODIES, ACTIVATABLE ANTI-CD71 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190202927
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 13, 2018
    Publication date: July 4, 2019
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190117789
    Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: August 30, 2018
    Publication date: April 25, 2019
    Inventors: LORI CARMAN, RACHEL HUMPHREY, W. MICHAEL KAVANAUGH, JONATHAN TERRETT, ANNIE YANG WEAVER, MATTHIAS WILL
  • Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
    Patent number: 10233244
    Abstract: The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 19, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Jason Gary Sagert, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
  • Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
    Patent number: 10179817
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 15, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • ANTIBODIES THAT BIND ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170326260
    Abstract: The invention relates generally to antibodies and antigen-binding fragments thereof that bind activatable antibodies and/or conjugated activatable antibodies and methods of making and using these antibodies that bind activatable antibodies and/or conjugated activatable antibodies.
    Type: Application
    Filed: July 26, 2017
    Publication date: November 16, 2017
    Inventors: Luc Roland Desnoyers, Tony W. Liang, Annie Yang Weaver
  • Antibodies that bind activatable antibodies and methods of use thereof
    Patent number: 9737623
    Abstract: The invention relates generally to antibodies and antigen-binding fragments thereof that bind activatable antibodies and/or conjugated activatable antibodies and methods of making and using these antibodies that bind activatable antibodies and/or conjugated activatable antibodies.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: August 22, 2017
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Luc Roland Desnoyers, Tony W. Liang, Annie Yang Weaver